Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Applied Health Economics and Health Policy
Erschienen in: Applied Health Economics and Health Policy 2/2015

01.04.2015 | Systematic Review

A Systematic Review on Cost Effectiveness of HIV Prevention Interventions in the United States

verfasst von: Ya-Lin A. Huang, Arielle Lasry, Angela B. Hutchinson, Stephanie L. Sansom

Erschienen in: Applied Health Economics and Health Policy | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

The Centers for Disease Control and Prevention (CDC) focus on funding HIV prevention interventions likely to have high impact on the HIV epidemic. In its most recent funding announcement to state and local health department grantees, CDC required that health departments allocate the majority of funds to four HIV prevention interventions: HIV testing, prevention with HIV-positives and their partners, condom distribution and policy initiatives.

Objective

We conducted a systematic review of the published literature to determine the extent of the cost-effectiveness evidence for each of those interventions.

Methodology

We searched for US-based studies published through October 2012. The studies that qualified for inclusion contained original analyses that reported costs per quality-adjusted life-year saved, life-year saved, HIV infection averted, or new HIV diagnosis. For each study, paired reviewers performed a detailed review and data extraction. We reported the number of studies related to each intervention and summarized key cost-effectiveness findings according to intervention type. Costs were converted to 2011 US dollars.

Results

Of the 50 articles that met the inclusion criteria, 33 related to HIV testing, 15 assessed prevention with HIV-positives and partners, three reported on condom distribution, and one reported on policy initiatives. Methodologies and cost-effectiveness metrics varied across studies and interventions, making them difficult to compare.

Conclusion

Our review provides an updated summary of the published evidence of cost effectiveness of four key HIV prevention interventions recommended by CDC. With the exception of testing-related interventions, including partner services, where economic evaluations suggest that testing often can be cost effective, more cost-effectiveness research is needed to help guide the most efficient use of HIV prevention funds.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Farnham PG, Holtgrave DR, Sansom SL, Hall HI. Medical costs averted by HIV prevention efforts in the United States, 1991–2006. J Acquir Immune Defic Syndr. 2010;54(5):565–7.CrossRefPubMed
2.
3.
Prejean J, Song R, Hernandez A, Ziebell R, Green T, Walker F, et al. Estimated HIV incidence in the United States, 2006–2009. PloS One. 2011;6(8):e17502.CrossRefPubMedCentralPubMed
4.
Hall HI, Green TA, Wolitski RJ, Holtgrave DR, Rhodes P, Lehman JS, et al. Estimated future HIV prevalence, incidence, and potential infections averted in the United States: a multiple scenario analysis. J Acquir Immune Defic Syndr. 2010;55(2):271–6.CrossRefPubMed
5.
National HIV/AIDS Strategy for the United States. Office of National AIDS Policy; 2010.
6.
7.
8.
9.
Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1–17.
10.
Bedimo AL, Pinkerton SD, Cohen DA, Gray B, Farley TA. Condom distribution: a cost-utility analysis. Int J STD AIDS. 2002;13(6):384–92.CrossRefPubMed
11.
Cohen DA, Wu SY, Farley TA. Structural interventions to prevent HIV/sexually transmitted disease: are they cost-effective for women in the southern United States? Sex Transm Dis. 2006;33(7 Suppl):S46–9.CrossRefPubMed
12.
Prabhu VS, Hutchinson AB, Farnham PG, Sansom SL. Sexually acquired HIV infections in the United States due to acute-phase HIV transmission: an update. AIDS. 2009;23(13):1792–4.CrossRefPubMed
13.
Hutchinson AB, Patel P, Sansom SL, Farnham PG, Sullivan TJ, Bennett B, et al. Cost-effectiveness of pooled nucleic acid amplification testing for acute HIV infection after third-generation HIV antibody screening and rapid testing in the United States: a comparison of three public health settings. PLoS Med. 2010;7(9):e1000342.CrossRefPubMedCentralPubMed
14.
Farnham PG, Sansom SL, Hutchinson AB. How much should we pay for a new HIV diagnosis? A mathematical model of HIV screening in US clinical settings. Med Decis Making. 2012;32(3):459–69.CrossRefPubMed
15.
Long EF. HIV screening via fourth-generation immunoassay or nucleic acid amplification test in the United States: a cost-effectiveness analysis. PloS One. 2011;6(11):16.CrossRef
16.
Juusola JL, Brandeau ML, Long EF, Owens DK, Bendavid E. The cost-effectiveness of symptom-based testing and routine screening for acute HIV infection in men who have sex with men in the USA. AIDS. 2011;25(14):1779–87.CrossRefPubMedCentralPubMed
17.
Sansom SL, Jamieson DJ, Farnham PG, Bulterys M, Fowler MG. Human immunodeficiency virus retesting during pregnancy: costs and effectiveness in preventing perinatal transmission. Obstet Gynecol. 2003;102(4):782–90.CrossRefPubMed
18.
Desai K, Sansom SL, Ackers ML, Stewart SR, Hall HI, Hu DJ, et al. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS. 2008;22(14):1829–39.CrossRefPubMed
19.
Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, Wang B, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis. 2009;48(6):806–15.CrossRefPubMedCentralPubMed
20.
Koppenhaver RT, Sorensen SW, Farnham PG, Sansom SL. The cost-effectiveness of pre-exposure prophylaxis in men who have sex with men in the United States: an epidemic model. J Acquir Immune Defic Syndr. 2011;58(2):e51–2.CrossRefPubMed
21.
Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373(9657):48–57.CrossRefPubMed
22.
Walensky RP, Ross EL, Kumarasamy N, Wood R, Noubary F, Paltiel AD, et al. The cost-effectiveness of treatment as prevention: analysis of the HPTN 052 trial. International AIDS Conference. Washington DC, US; 2012.
23.
Granich R, Kahn JG, Bennett R, Holmes CB, Garg N, Serenata C, et al. Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011–2050. PLoS One. 2012;7(2):e30216.CrossRefPubMedCentralPubMed
24.
Silva A, Glick NR, Lyss SB, Hutchinson AB, Gift TL, Pealer LN, et al. Implementing an HIV and sexually transmitted disease screening program in an emergency department. Ann Emerg Med. 2007;49(5):564–72.CrossRefPubMed
25.
Lurie P, Avins AL, Phillips KA, Kahn JG, Lowe RA, Ciccarone D. The cost-effectiveness of voluntary counseling and testing of hospital inpatients for HIV infection. JAMA. 1994;272(23):1832–8.CrossRefPubMed
26.
Owens DK, Nease RF Jr, Harris RA. Cost-effectiveness of HIV screening in acute care settings. Arch Intern Med. 1996;156(4):394–404.CrossRefPubMed
27.
Phillips KA, Fernyak S. The cost-effectiveness of expanded HIV counselling and testing in primary care settings: a first look. AIDS. 2000;14(14):2159–69.CrossRefPubMed
28.
Walensky RP, Weinstein MC, Kimmel AD, Seage GR 3rd, Losina E, Sax PE, et al. Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. Am J Med. 2005;118(3):292–300.CrossRefPubMed
29.
Walensky RP, Losina E, Malatesta L, Barton GE, O’Connor CA, Skolnik PR, et al. Effective HIV case identification through routine HIV screening at urgent care centers in Massachusetts. Am J Public Health. 2005;95(1):71–3.CrossRefPubMedCentralPubMed
30.
Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352(6):570–85.CrossRefPubMed
31.
Paltiel AD, Weinstein MC, Kimmel AD, Seage GR 3rd, Losina E, Zhang H, et al. Expanded screening for HIV in the United States—an analysis of cost-effectiveness. N Engl J Med. 2005;352(6):586–95.CrossRefPubMed
32.
Paltiel AD, Walensky RP, Schackman BR, Seage GR 3rd, Mercincavage LM, Weinstein MC, et al. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med. 2006;145(11):797–806.CrossRefPubMed
33.
Holtgrave DR. Costs and consequences of the US Centers for Disease Control and Prevention’s recommendations for opt-out HIV testing. PLoS Med. 2007;4(6):e194.CrossRefPubMedCentralPubMed
34.
Brown J, Shesser R, Simon G, Bahn M, Czarnogorski M, Kuo I, et al. Routine HIV screening in the emergency department using the new US Centers for Disease Control and Prevention Guidelines: results from a high-prevalence area. J Acquir Immune Defic Syndr. 2007;46(4):395–401.CrossRefPubMed
35.
Farnham PG, Hutchinson AB, Sansom SL, Branson BM. Comparing the costs of HIV screening strategies and technologies in health-care settings. Public Health Rep. 2008;123(Suppl 3):51–62.PubMedCentralPubMed
36.
Sanders GD, Bayoumi AM, Holodniy M, Owens DK. Cost-effectiveness of HIV screening in patients older than 55 years of age. Ann Intern Med. 2008;148(12):889–903.CrossRefPubMedCentralPubMed
37.
Long EF, Brandeau ML, Owens DK. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med. 2010;153(12):778–89.CrossRefPubMedCentralPubMed
38.
Sanders GD, Anaya HD, Asch S, Hoang T, Golden JF, Bayoumi AM, et al. Cost-effectiveness of strategies to improve HIV testing and receipt of results: economic analysis of a randomized controlled trial. J Gen Intern Med. 2010;25(6):556–63.CrossRefPubMedCentralPubMed
39.
Torres GW, Heffelfinger JD, Pollack HA, Barrera SG, Rothman RE. HIV screening programs in US emergency departments: a cross-site comparison of structure, process, and outcomes. Ann Emerg Med. 2011;58(1 Suppl 1):S104–13.CrossRefPubMed
40.
Hsieh YH, Jung JJ, Shahan JB, Pollack HA, Hairston HS, Moring-Parris D, et al. Outcomes and cost analysis of 3 operational models for rapid HIV testing services in an academic inner-city emergency department. Ann Emerg Med. 2011;58(1 Suppl 1):S133–9.CrossRefPubMed
41.
Hutchinson AB, Farnham PG, Lyss SB, White DA, Sansom SL, Branson BM. Emergency department HIV screening with rapid tests: a cost comparison of alternative models. AIDS Educ Prev. 2011;23(3 Suppl):58–69.CrossRefPubMed
42.
Prabhu VS, Farnham PG, Hutchinson AB, Soorapanth S, Heffelfinger JD, Golden MR, et al. Cost-effectiveness of HIV screening in STD clinics, emergency departments, and inpatient units: a model-based analysis. PLoS One. 2011;6(5):e19936.CrossRefPubMedCentralPubMed
43.
Walensky RP, Morris BL, Reichmann WM, Paltiel AD, Arbelaez C, Donnell-Fink L, et al. Resource utilization and cost-effectiveness of counselor- vs. provider-based rapid point-of-care HIV screening in the emergency department. PLoS One. 2011;6(10):12.CrossRef
44.
Shrestha RK, Clark HA, Sansom SL, Song B, Buckendahl H, Calhoun CB, et al. Cost-effectiveness of finding new HIV diagnoses using rapid HIV testing in community-based organizations. Public Health Rep. 2008;123(Suppl 3):94–100.PubMedCentralPubMed
45.
Golden MR, Gift TL, Brewer DD, Fleming M, Hogben M, St Lawrence JS, et al. Peer referral for HIV case-finding among men who have sex with men. AIDS. 2006;20(15):1961–8.CrossRefPubMed
46.
47.
Shrestha RK, Sansom SL, Richardson-Moore A, French PT, Scalco B, Lalota M, et al. Costs of voluntary rapid HIV testing and counseling in jails in 4 states—advancing HIV Prevention Demonstration Project, 2003–2006. Sex Transm Dis. 2009;36(2 Suppl):S5–8.CrossRefPubMed
48.
Shrestha RK, Sansom SL, Schulden JD, Song B, Smith LC, Ramirez R, et al. Costs and effectiveness of finding new HIV diagnoses by using rapid testing in transgender communities. AIDS Educ Prev. 2011;23(3 Suppl):49–57.CrossRefPubMed
49.
Schackman BR, Metsch LR, Colfax GN, Leff JA, Wong A, Scott CA, et al. The cost-effectiveness of rapid HIV testing in substance abuse treatment: results of a randomized trial. Drug Alcohol Depend. 2012;6:6.
50.
Cipriano LE, Zaric GS, Holodniy M, Bendavid E, Owens DK, Brandeau ML. Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users. PLoS One. 2012;7(9):18.CrossRef
51.
Grobman WA, Garcia PM. The cost-effectiveness of voluntary intrapartum rapid human immunodeficiency virus testing for women without adequate prenatal care. Am J Obstet Gynecol. 1999;181(5 Pt 1):1062–71.CrossRefPubMed
52.
Immergluck LC, Cull WL, Schwartz A, Elstein AS. Cost-effectiveness of universal compared with voluntary screening for human immunodeficiency virus among pregnant women in Chicago. Pediatrics. 2000;105(4):E54.CrossRefPubMed
53.
Zaric GS, Bayoumi AM, Brandeau ML, Owens DK. The cost effectiveness of voluntary prenatal and routine newborn HIV screening in the United States. J Acquir Immune Defic Syndr. 2000;25(5):403–16.CrossRefPubMed
54.
Resch S, Altice FL, Paltiel AD. Cost-effectiveness of HIV screening for incarcerated pregnant women. J Acquir Immune Defic Syndr. 2005;38(2):163–73.CrossRefPubMed
55.
Myers ER, Thompson JW, Simpson K. Cost-effectiveness of mandatory compared with voluntary screening for human immunodeficiency virus in pregnancy. Obstet Gynecol. 1998;91(2):174–81.CrossRefPubMed
56.
Gopalappa C, Farnham PG, Hutchinson AB, Sansom SL. Cost effectiveness of the National HIV/AIDS Strategy goal of increasing linkage to care for HIV-infected persons. J Acquir Immune Defic Syndr. 2012;61(1):99–105.CrossRefPubMed
57.
Lee MB, Leibowitz A, Rotheram-Borus MJ. Cost-effectiveness of a behavioral intervention for seropositive youth. AIDS Educ Prev. 2005;17(2):105–18.CrossRefPubMed
58.
Marseille E, Shade SB, Myers J, Morin S. The cost-effectiveness of HIV prevention interventions for HIV-infected patients seen in clinical settings. J Acquir Immune Defic Syndr. 2011;56(3):e87–94.CrossRefPubMed
59.
Rutherford GW, Woo JM, Neal DP, Rauch KJ, Geoghegan C, McKinney KC, et al. Partner notification and the control of human immunodeficiency virus infection. Two years of experience in San Francisco. Sex Transm Dis. 1991;18(2):107–10.CrossRefPubMed
60.
Pavia AT, Benyo M, Niler L, Risk I. Partner notification for control of HIV: results after 2 years of a statewide program in Utah. Am J Public Health. 1993;83(10):1418–24.CrossRefPubMedCentralPubMed
61.
Spencer NE, Hoffman RE, Raevsky CA, Wolf FC, Vernon TM. Partner notification for human immunodeficiency virus infection in Colorado: results across index case groups and costs. Int J STD AIDS. 1993;4(1):26–32.PubMed
62.
Toomey KE, Peterman TA, Dicker LW, Zaidi AA, Wroten JE, Carolina J. Human immunodeficiency virus partner notification. Cost and effectiveness data from an attempted randomized controlled trial. Sex Transm Dis. 1998;25(6):310–6.CrossRefPubMed
63.
Varghese B, Peterman TA, Holtgrave DR. Cost-effectiveness of counseling and testing and partner notification: a decision analysis. AIDS. 1999;13(13):1745–51.CrossRefPubMed
64.
Ahrens K, Kent CK, Kohn RP, Nieri G, Reynolds A, Philip S, et al. HIV partner notification outcomes for HIV-infected patients by duration of infection, San Francisco, 2004–2006. J Acquir Immune Defic Syndr. 2007;46(4):479–84.CrossRefPubMed
65.
Shrestha RK, Begley EB, Hutchinson AB, Sansom SL, Song B, Voorhees K, et al. Costs and effectiveness of partner counseling and referral services with rapid testing for HIV in Colorado and Louisiana, United States. Sex Transm Dis. 2009;36(10):637–41.CrossRefPubMed
66.
Shrestha RK, Sansom SL, Kimbrough L, Hutchinson AB, Daltry D, Maldonado W, et al. Cost-effectiveness of using social networks to identify undiagnosed HIV infection among minority populations. J Public Health Manag Pract. 2010;16(5):457–64.CrossRefPubMed
67.
Halpern MT, Read JS, Ganoczy DA, Harris DR. Cost-effectiveness of cesarean section delivery to prevent mother-to-child transmission of HIV-1. AIDS. 2000;14(6):691–700.CrossRefPubMed
68.
Mrus JM, Goldie SJ, Weinstein MC, Tsevat J. The cost-effectiveness of elective Cesarean delivery for HIV-infected women with detectable HIV RNA during pregnancy. AIDS. 2000;14(16):2543–52.CrossRefPubMed
69.
Holtgrave DR, Wolitski RJ, Pals SL, Aidala A, Kidder DP, Vos D, et al. Cost-utility analysis of the housing and health intervention for homeless and unstably housed persons living with HIV. AIDS Behav. 2012;16:16.
70.
Holtgrave DR, Maulsby C, Kharfen M, Jia Y, Wu C, Opoku J, et al. Cost-utility analysis of a female condom promotion program in Washington,DC. AIDS Behav. 2012;16(5):1115–20.CrossRefPubMed
Metadaten
Titel
A Systematic Review on Cost Effectiveness of HIV Prevention Interventions in the United States
verfasst von
Ya-Lin A. Huang
Arielle Lasry
Angela B. Hutchinson
Stephanie L. Sansom
Publikationsdatum
01.04.2015
Verlag
Springer International Publishing
Erschienen in
Applied Health Economics and Health Policy / Ausgabe 2/2015
Print ISSN: 1175-5652
Elektronische ISSN: 1179-1896
DOI
https://doi.org/10.1007/s40258-014-0142-5

Weitere Artikel der Ausgabe 2/2015

Applied Health Economics and Health Policy 2/2015 Zur Ausgabe

Original Research Article

A Prediction Model of Childhood Immunization Rates

Original Research Article

Potential Savings in Prescription Drug Costs for Hypertension, Hyperlipidemia, and Diabetes Mellitus by Equivalent Drug Substitution in Austria: A Nationwide Cohort Study

Original Research Article

Economic Analysis of Thrombo inCode, a Clinical–Genetic Function for Assessing the Risk of Venous Thromboembolism

Review Article

The geko™ Electro-Stimulation Device for Venous Thromboembolism Prophylaxis: A NICE Medical Technology Guidance

Original Research Article

Cost-Effectiveness and Value of Information Analysis of Nutritional Support for Preventing Pressure Ulcers in High-risk Patients: Implement Now, Research Later

Original Research Article

Prospective Randomized Controlled Trial Comparing the Outcomes and Costs of Two Eyecare Adherence Interventions in Diabetes Patients